3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1- butanesulfonate (BAY 59-3074): A novel cannabinoid CB1/CB2 receptor partial agonist with antihyperalgesic and antiallodynic effects

Journal of Pharmacology and Experimental Therapeutics

Volumn 310, Issue 2, 2004, Pages 620-632

  De Vry, Jean ^a,c   Denzer, Dirk ^a   Reissmueller, Elke ^a   Eijckenboom, Maud ^a   Heil, Markus ^b   Meier, Heinrich ^b   Mauler, Frank ^a  

^a Central Nervous System Research   (Germany)

^b Medicinal Chemistry   (Germany)

^c GRÜNENTHAL GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 HYDROXYMETHYLINDANYL 4 OXY)PHENYL 4,4,4 TRIFLUORO 1 BUTANESULFONATE; 3 [2 CYANO 3 (TRIFLUOROMETHYL)PHENOXY]PHENYL 4,4,4 TRIFLUORO 1 BUTANESULFONATE; BAY 387271; BAY 593074; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CARRAGEENAN; FREUND ADJUVANT; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); PARTIAL AGONIST; RIMONABANT; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSOCIATION; BINDING ASSAY; CHRONIC PAIN; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOLERANCE; DRUG WITHDRAWAL; HOT PLATE TEST; HUMAN; HUMAN TISSUE; HYPERALGESIA; HYPOTHERMIA; INFLAMMATION; MALE; MECHANICAL STIMULATION; NERVE INJURY; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL NERVE; THERMAL STIMULATION; TIBIAL NERVE; TITRIMETRY; WITHDRAWAL SYNDROME;

ALKANESULFONATES; ANALGESICS, NON-NARCOTIC; ANIMALS; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERALGESIA; MALE; NITRILES; PAIN MEASUREMENT; PROTEIN BINDING; RATS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 2342498975     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.062836     Document Type: Article

References (40)

1. 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 278:1290-1295.
2. Bennett GI and Xie YK (1988) A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33:87-107.
3. 2 exert antiopioid effects in the Freund's adjuvant-induced arthritic rat model of chronic pain. Br J Pharmacol 128:1252-1258.
4. Bridges D, Ahmad K, and Rice AS (2001) The synthetic cannabinoid WIN 55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 133:586-594.
5. 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain. Eur J Pharm 323:R3-R4.
6. Clayton N, Marshall FH, Bountra C, and O'Shaughnessy CT (2002) CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96:253-260.
7. Conti S, Costa B, Colleoni M, Parolaro D, and Giagnoni G (2002) Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br JPharmacol 135:181-187.
8. Decosterd I and Woolf CJ (2000) Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87:149-158.
9. De Vry J and Jentzsch KR (2002) Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist. Eur J Pharmacol 457:147-152.
10. 1 receptor ligands in a drug discrimination paradigm. Behav Pharmacol 14:471-476.
11. De Vry J, Jentzsch KR, Kuhl E, and Eckel G (2004a) Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol 15:1-12.
12. De Vry J, Kuhl E, Franken-Kunkel P, and Eckel G (2004b) Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur J Pharmacol 491:137-148.
13. 35S]GTPγS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci 12:2079-2086.
14. 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92:91-100.
15. Gaoini Y and Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646-1647.
16. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, and Volkow ND (1999) Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 288:478-483.
17. Hargreaves K, Dubner R, Brown F, Flores C, and Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77-88.
18. 1 receptor to reverse carrageenan-induced thermal hyperalgesia in rats. Soc Neurosci Abstr 25:1197.
19. Herzberg U, Eliav E, Bennett GJ, and Kopin IJ (1997) The analgesic effects of R(+)-WIN 55,212.2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 221:157-160.
20. Hofmann HA, De Vry J, Siegling A, Spreyer P, and Denzer D (2003) Pharmacological sensitivity and gene expression analysis of the tibial nerve injury model of neuropathic pain. Eur J Pharmacol 470:17-25.
21. Johanek LM, Heitmiller DR, Turner M, Nader N, Hodges J, and Simone DA (2001) Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain 93:303-315.
22. Kim SH and Chung JM (1992) An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50:355-363.
23. Li J, Daughters RS, Bullis C, Bengiamin R, Stucky MW, Brennan J, and Simone DA (1999) The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain 81:25-33.
24. Mao J, Price DD, Lu J, Keniston L, and Mayer DJ (2000) Two distinctive antinociceptive systems in rats with pathological pain. Neurosci Lett 280:13-16.
25. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R, and Ward SJ (1991) Behavioral, biochemical and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40:471-478.
26. Martin TJ and Eisenach JC (2001) Pharmacology of opioid and nonopioid analgesics in chronic pain states. J Pharmacol Exp Ther 299:811-817.
27. Martin WJ, Loo CM, and Basbaum AI (1999) Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain 82:199-205.
28. Mauler F, Mittendorf J, Horváth E, and De Vry J (2002) Characterization of the diarylether sulfonylester (-)-(R)-3-(2- hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol Exp Ther 302:1-10.
29. Monhemius R, Azami J, Green DL, and Roberts MH (2001) CB1 receptor mediated analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain. Brain Res 908:67-74.
30. Pertwee RG (1999) Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6:635-664.
31. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569-611.
32. 9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63:PL1-6.
33. Piomelli D, Giuffrida A, Calignano A, and Rodríguez de Fonseca F (2000) The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 21:218-224.
34. Richardson JD (2000) Cannabinoids modulate pain by multiple mechanisms of action. J Pain 1:2-14.
35. Richardson JD, Aanonsen L, and Hargreaves KM (1998) Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 345:145-153.
36. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
37. 1 receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 415:R5-R7.
38. Sindrup SH and Jensen TS (1999) Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83:389-400.
39. 9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav 60:183-191.
40. Wiley JL, Barrett RL, Lowe J, Balster RL, and Martin BR (1995) Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 34:669-676.